Wed, Apr 24th 2024
Galderma starts 2024 with impressive growth, reporting over $1 billion in sales and confirming its financial outlook for the year.
Galderma Group AG, headquartered in Zug, Switzerland, has reports first-quarter net sales reaching $1.071 billion, marking the first time the company has surpassed the $1 billion milestone in the initial three months of a year. According to a press release.
This represents a significant year-on-year growth of 12.4% on a constant currency basis.
Injectable Aesthetics led with a 19.3% growth, achieving sales of $511 million. Neuromodulators, rose to $263 million, and Fillers and Biostimulators at $248 million.
Dermatological Skincare also showed substantial growth, posting $351 million in sales, an 8.4% increase. Therapeutic Dermatology contributed $209 million, up by 4.1%.
Internationally, Galderma saw a significant 16.5% increase in sales, demonstrating strong market performance outside the U.S., where growth also accelerated, contributing to a 6.4% rise in sales.
Amidst this financial growth, Galderma reaffirmed its 2024 full-year guidance, anticipating a 7-10% increase in net sales year on year with a core EBITDA margin consistent with 2023.
English 
German 
French 
Spanish 
Arabic